Neurocrine Biosciences
NBIX
#1490
Rank
A$20.72 B
Marketcap
A$203.85
Share price
0.84%
Change (1 day)
-4.69%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$10.41

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$10.09. In 2025 the company made an earnings per share (EPS) of A$6.90 an increase over its 2024 EPS that were of A$4.84.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$10.4150.86%
2025A$6.9042.6%
2024A$4.8433.07%
2023A$3.6357.76%
2022A$2.3069.47%
2021A$1.36-78.21%
2020A$6.24990%
2019A$0.5781.82%
2018A$0.31-113.5%
2017A-$2.330.62%
2016A-$2.3257.28%
2015A-$1.4725.61%
2014A-$1.1718.84%
2013A-$0.99-1085.71%
2012A$0.10

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.09-89.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$5.11-49.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$42.77 323.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.07-89.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.91-128.79%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$6.91-31.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$10.80-207.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.68-73.39%๐Ÿ‡ฌ๐Ÿ‡ง UK